{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:53:55Z","timestamp":1790096035385,"version":"4.0.1"},"reference-count":22,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Although pharmacovigilance signals and a strong pathophysiological rationale have suggested a potential risk of arterial dissections or aneurysms associated with angiogenesis inhibitors, this association deserves to be further investigated through clinical practice evidence studies.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the association between exposure to angiogenesis inhibitors and the occurrence of arterial dissections or aneurysms in patients treated for metastatic colorectal cancer (mCRC).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n A nested case-control study was conducted within a cohort of adults initiating targeted therapy (angiogenesis or epidermal growth factor receptor inhibitors) for mCRC between January 1, 2012, and December 31, 2017. Data were analyzed from April 2021 through August 2023. Data were drawn from the French nationwide Syst\u00e8me National des Donn\u00e9es de Sant\u00e9 database, which combines health insurance and hospital discharge records. Cases of arterial dissection or aneurysm were identified through 2019 and matched with up to 10 controls by age, sex, and time since cohort entry.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n The angiogenesis inhibitors indicated for mCRC in France (ie, bevacizumab, aflibercept, ramucirumab, and regorafenib) were considered. Exposure was defined using 3 criteria: exposure at any point (exposed vs unexposed), recency (current, past, or unexposed), and cumulative duration of exposure (quartiles). Exposure periods were estimated using recommended administration schedules or drug elimination times.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was incident hospitalization for arterial dissection or aneurysm, identified through hospital discharge diagnoses. Conditional logistic regression models were applied to estimate the association between exposure to angiogenesis inhibitors and the occurrence of arterial dissections or aneurysms, expressed as odds ratios (ORs) with 95% CIs.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of the 34\u202f733 patients included in the cohort, 195 incident cases (0.6%) were matched with 1950 controls. The study population (2145 patients) included 1562 male patients (72.8%); the median (IQR) age was 69 (63-73) years for cases and 68 (62-73) years for controls. Considering exposure at any point, 141 cases (72.3%) and 1381 controls (70.8%) were exposed to angiogenesis inhibitors; after adjustment for cardiovascular risk level, no association was observed between exposure and the occurrence of arterial events (OR, 1.07; 95% CI, 0.75-1.52). No associations were found with either recency or cumulative duration of exposure, regardless of the exposure estimation method.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this case-control study of arterial dissections or aneurysms in patients receiving targeted therapy for mCRC, the lack of association with angiogenesis inhibitor exposure was reassuring, given the established benefits of these drugs, particularly bevacizumab, for this indication.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.46960","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T16:30:58Z","timestamp":1764865858000},"page":"e2546960","source":"Crossref","is-referenced-by-count":1,"title":["Angiogenesis Inhibitors and Arterial Dissection or Aneurysm in Patients With Metastatic Colorectal Cancer"],"prefix":"10.1001","volume":"8","author":[{"given":"Allison","family":"Singier","sequence":"first","affiliation":[{"name":"Univ. Bordeaux, INSERM, BPH, U1219, AHeaD Team, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Jarne Munoz","sequence":"additional","affiliation":[{"name":"Univ. Bordeaux, INSERM, BPH, U1219, AHeaD Team, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Maumus-Robert","sequence":"additional","affiliation":[{"name":"Univ. Bordeaux, INSERM, BPH, U1219, AHeaD Team, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"B\u00e9rard","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, P\u00f4le de chirurgie, Service de chirurgie vasculaire et endovasculaire, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Pariente","sequence":"additional","affiliation":[{"name":"Univ. Bordeaux, INSERM, BPH, U1219, AHeaD Team, Bordeaux, France"},{"name":"CHU de Bordeaux, P\u00f4le de sant\u00e9 publique, Service de pharmacologie m\u00e9dicale, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Bezin","sequence":"additional","affiliation":[{"name":"Univ. Bordeaux, INSERM, BPH, U1219, AHeaD Team, Bordeaux, France"},{"name":"CHU de Bordeaux, P\u00f4le de sant\u00e9 publique, Service de pharmacologie m\u00e9dicale, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Kempf","sequence":"additional","affiliation":[{"name":"AP-HP, H\u00f4pital Henri-Mondor, Service d\u2019oncologie m\u00e9dicale, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernelle","family":"Noize","sequence":"additional","affiliation":[{"name":"Univ. Bordeaux, INSERM, BPH, U1219, AHeaD Team, Bordeaux, France"},{"name":"CHU de Bordeaux, P\u00f4le de sant\u00e9 publique, Service de pharmacologie m\u00e9dicale, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"issue":"5","key":"zoi251273r1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation.","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"6","key":"zoi251273r2","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors.","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"issue":"7347","key":"zoi251273r3","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10144","article-title":"Molecular mechanisms and clinical applications of angiogenesis.","volume":"473","author":"Carmeliet","year":"2011","journal-title":"Nature"},{"issue":"6","key":"zoi251273r5","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1097\/HJH.0000000000000550","article-title":"Large artery stiffness and hypertension after antiangiogenic drugs: influence on cancer progression.","volume":"33","author":"Alivon","year":"2015","journal-title":"J Hypertens"},{"issue":"5","key":"zoi251273r6","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1177\/1358863X211006470","article-title":"Arterial aneurysm and dissection with systemic vascular endothelial growth factor inhibitors: a review of cases reported to the FDA Adverse Event Reporting System and published in the literature.","volume":"26","author":"Cheng","year":"2021","journal-title":"Vasc Med"},{"issue":"8","key":"zoi251273r7","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1161\/CIRCULATIONAHA.116.025144","article-title":"Association between aortic dissection and systemic exposure of vascular endothelial growth factor pathway inhibitors in the Japanese Adverse Drug Event Report Database.","volume":"135","author":"Oshima","year":"2017","journal-title":"Circulation"},{"issue":"5","key":"zoi251273r8","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1001\/jamaoncol.2021.0210","article-title":"Association between antiangiogenic drugs used for cancer treatment and artery dissections or aneurysms.","volume":"7","author":"Guyon","year":"2021","journal-title":"JAMA Oncol"},{"issue":"23","key":"zoi251273r9","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.020844","article-title":"Aneurysm and artery dissection following the use of vascular endothelial growth factor inhibitor: a real-world analysis using a spontaneous reporting system.","volume":"10","author":"Wang","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"zoi251273r10","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.707","article-title":"Tyrosine kinase inhibitors targeting vascular endothelial growth factor and the risk of aortic dissection: a pharmacovigilance analysis.","volume":"9","author":"D\u00f6rks","year":"2021","journal-title":"Pharmacol Res Perspect"},{"issue":"10","key":"zoi251273r15","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.dld.2019.05.035","article-title":"Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR).","volume":"51","author":"Phelip","year":"2019","journal-title":"Dig Liver Dis"},{"issue":"6","key":"zoi251273r17","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.therap.2023.01.009","article-title":"Performing pharmacoepidemiological studies using the French health insurance data warehouse (SNDS): how to translate guidelines into practice.","volume":"78","author":"de Germay","year":"2023","journal-title":"Therapie"},{"issue":"7","key":"zoi251273r18","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.jacc.2018.12.012","article-title":"Short-term risk of aortoiliac aneurysm or dissection associated with fluoroquinolone use.","volume":"73","author":"Maumus-Robert","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"34","key":"zoi251273r19","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"11","key":"zoi251273r20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.45977","article-title":"Aneurysm and artery dissection after oral VEGFR-TKI use in adults with cancer.","volume":"6","author":"Kang","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zoi251273r21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.0940","article-title":"Vascular endothelial growth factor inhibitors and the risk of aortic aneurysm and aortic dissection.","volume":"7","author":"Wu","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"5","key":"zoi251273r22","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s11523-023-00986-2","article-title":"Impact of cardiovascular comorbidities on the effectiveness and safety of bevacizumab in older patients with metastatic colorectal cancer.","volume":"18","author":"Gouverneur","year":"2023","journal-title":"Target Oncol"},{"key":"zoi251273r4","first-page":"1161","volume-title":"Goodman & Gilman\u2019s: The Pharmacological Basis of Therapeutics","author":"Brunton","year":"2018","edition":"13th ed"},{"key":"zoi251273r11","unstructured":"Gouvernement du Canada SC. R\u00e9sum\u00e9 de l\u2019examen de l\u2019innocuit\u00e9: Inhibiteurs de la tyrosine kinase du r\u00e9cepteur du facteur de croissance de l\u2019endoth\u00e9lium vasculaire. Accessed October 6, 2025. https:\/\/hpr-rps.hres.ca\/reg-content\/resume-examen-innocuite-detail.php?lang=fr&linkID=SSR00213"},{"key":"zoi251273r12","unstructured":"European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC): July 8-11, 2019. Accessed October 6, 2025. https:\/\/www.ema.europa.eu\/en\/events\/pharmacovigilance-risk-assessment-committee-prac-8-11-july-2019"},{"key":"zoi251273r13","unstructured":"US Food and Drug Administration. January-March 2020\u2014potential signals of serious risks\/new safety information identified by the FDA Adverse Event Reporting System (FAERS). Accessed October 6, 2025. https:\/\/www.fda.gov\/drugs\/fdas-adverse-event-reporting-system-faers\/january-march-2020-potential-signals-serious-risksnew-safety-information-identified-fda-adverse"},{"key":"zoi251273r14","unstructured":"UK Medicines and Healthcare Products Regulatory Agency. Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection. Accessed October 6, 2025. https:\/\/www.gov.uk\/drug-safety-update\/systemically-administered-vegf-pathway-inhibitors-risk-of-aneurysm-and-artery-dissection"},{"key":"zoi251273r16","unstructured":"Equator Network. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Checklist of items that should be included in reports of case-control studies. Accessed October 6, 2025. https:\/\/www.equator-network.org\/wp-content\/uploads\/2015\/10\/STROBE_checklist_v4_case-control.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2842301\/singier_2025_oi_251273_1764102550.85009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T16:31:00Z","timestamp":1764865860000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2842301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.46960","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]}}}